Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. [electronic resource]
Producer: 20140815Description: 53-63 p. digitalISSN:- 1536-4828
- Angiogenesis Inhibitors -- administration & dosage
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Blotting, Western
- Cell Line
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Deoxycytidine -- administration & dosage
- Down-Regulation -- drug effects
- Drug Evaluation, Preclinical -- methods
- Enzyme Activation -- drug effects
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Gabexate -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Interleukin-8 -- genetics
- Matrix Metalloproteinase 2 -- genetics
- Matrix Metalloproteinase 9 -- genetics
- NF-kappa B -- antagonists & inhibitors
- Pancreatic Neoplasms -- drug therapy
- Proto-Oncogene Proteins c-akt -- metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Serine Proteinase Inhibitors -- administration & dosage
- Vascular Endothelial Growth Factor A -- genetics
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.